FreeScore your brand plan before management does. Send me the scorecard
In short: market access is the work of getting a medicine paid for and made available to the patients who need it. It covers pricing, reimbursement and insurance coverage, national and hospital formularies, public tenders and health technology assessment. Approval says a product may be sold; access decides whether it will be used. Payers want evidence of value against current practice and a budget they can afford, so access work starts years before launch. In Saudi Arabia, the path runs through SFDA pricing, NUPCO procurement, hospital pharmacy and therapeutics committees, and private insurance coverage.
A new medicine is approved. The launch meeting is booked, the sales force is trained, the materials are printed. Six months later sales are a fraction of forecast. The physicians liked the data. The problem was elsewhere: the product was not on the hospital formulary, the tender had closed before it was priced, and insurers had not decided whether to cover it. The launch did not have a sales problem. It had an access problem.
Market access used to be a back-office pricing task. Today it is one of the most important commercial functions in pharma, because health systems everywhere are under budget pressure and decide more carefully what they pay for. This guide explains what market access is, who decides, what evidence they need, the main access routes, how access works in Saudi Arabia, how the team is organised, how access is measured, and how to build an access plan. It connects closely with the go-to-market strategy and the pharma marketing strategy.
What Is Market Access in Pharma?
Market access means the right patients can get the medicine, at a price the health system accepts and the company can sustain.
Market access is the set of activities that secure a medicine’s availability and funding in a health system. It includes setting and defending the price, obtaining reimbursement or insurance coverage, getting listed on national and hospital formularies, winning public tenders, and passing health technology assessment where it exists. Its output is simple to describe and hard to achieve: patients for whom the medicine is right can actually receive it.
Access is different from regulatory approval. The regulator asks whether the product is safe, effective and of acceptable quality. Access decision makers ask further questions: is it better than what we use now, for which patients, by how much, at what cost, and can we afford it within our budget? A product can pass the first test and fail the second.
| Regulatory approval | Market access | |
|---|---|---|
| Question | May this product be sold? | Will the system pay for it and make it available? |
| Decision maker | Medicines regulator | Pricing authority, payers, insurers, procurement bodies, hospital committees |
| Evidence | Safety, efficacy, quality | Comparative effectiveness, cost-effectiveness, budget impact, unmet need |
| Outcome | Marketing authorisation | Price, coverage, formulary listing, tender award, conditions of use |
Who Makes Market Access Decisions?
Several groups, each deciding something different. Map them by what they decide and what they need, not by job title.
| Decision maker | What they decide | What they need from you |
|---|---|---|
| Pricing authority | The maximum or official price | Prices in reference countries, comparisons with alternatives, economic data |
| National payer or insurer | Whether and how the product is covered or reimbursed | Value evidence, budget impact, proposed patient group |
| HTA body | A recommendation on value, sometimes binding | Clinical and economic dossier, models, comparator data |
| Procurement body | Tender awards, volumes and prices for public purchasing | Compliant tender submission, price, supply reliability |
| Hospital pharmacy and therapeutics committee | Formulary inclusion and conditions of use in that hospital | Clinical evidence, place in therapy, cost to the hospital budget, specialist support |
| Prescribers and specialists | Requests for listing; use within the rules | Scientific evidence and support, usually through medical affairs |
Prescribers do not make access decisions alone, but they influence them. A formulary committee usually looks for a specialist who requests the product and can explain where it fits. That is one reason medical science liaisons and access teams work closely, within the rules that keep scientific exchange separate from promotion.
What Evidence Do Payers Need?
Payers want proof of value against what they use today, and a budget they can afford. Clinical data alone is rarely enough.
Health economics gives payers a common language. The foundations of cost-effectiveness analysis in medicine were set out by Milton Weinstein and William Stason in the New England Journal of Medicine in 1977: compare the extra cost of a treatment with the extra health it produces, often measured in quality-adjusted life years (QALYs). The World Health Organization’s guideline on country pharmaceutical pricing policies (first published in 2015) describes the pricing tools governments use, including external reference pricing and health technology assessment. Most access evidence packages are built around four questions:
| Payer question | Evidence that answers it |
|---|---|
| Is there a real unmet need? | Disease burden, epidemiology, gaps in current treatment, patient and system costs |
| Is it better than what we use now, and for whom? | Head-to-head or indirect comparisons, subgroup data, real-world evidence |
| Is it worth the price? | Cost-effectiveness analysis, cost per outcome, cost offsets such as avoided hospital stays |
| Can we afford it? | Budget impact model for the payer’s own population and budget period |
These answers usually come together in a value dossier: a structured document that covers the disease, the product, the clinical evidence, the comparisons, the economic models and the proposed place in therapy. Global teams often build a core dossier; local teams adapt it to each country’s population, comparators, prices and submission rules. The budget impact model almost always needs local data, which is why local access teams start collecting it early.
What Are the Main Market Access Routes?
Five routes appear in most markets: pricing, reimbursement or coverage, formulary listing, tenders and HTA. Each country combines them differently.
| Route | What it is | Typical tools |
|---|---|---|
| Pricing | The official or maximum price, set or approved by an authority | External reference pricing, internal comparison with alternatives, economic review |
| Reimbursement and coverage | Whether a public payer or insurer pays, and the patient’s share | Positive or negative lists, co-payments, conditions of use |
| Formulary listing | Inclusion on a national, insurer or hospital list of approved medicines | Committee review, place in therapy, restrictions to specialists or indications |
| Tenders | Competitive public purchasing for volumes and prices | Technical and price evaluation, supply commitments |
| Health technology assessment | Structured evaluation of value used to inform the decisions above | Clinical and economic dossiers, models, appraisal committees |
Companies and payers also agree more flexible arrangements, often called managed entry agreements: discounts linked to volume, caps on total spend, or payment linked to outcomes in real patients. They let a payer give access while uncertainty about value or budget is still high. Whether they are available, and in what form, depends on the country and the payer.
FreeScore your brand plan before management does. Send me the scorecard
How Does Market Access Work in Saudi Arabia?
SFDA registers and prices; NUPCO handles consolidated public purchasing; hospital committees decide formulary use; private coverage sits under the Council of Health Insurance and insurers.
The figures and rules in this section come from SFDA’s own summary of its pricing and reimbursement process, prepared for the Pharmaceutical Pricing and Reimbursement Information (PPRI) network in 2024. Rules are revised from time to time, so treat this as a map of how the system works and check the current SFDA, NUPCO and Council of Health Insurance requirements for your product before you plan.
Pricing. After registration review, SFDA’s pricing and pharmacoeconomics directorate studies the pricing request and a pharmaceuticals pricing committee decides. For innovative products, the summary describes a hybrid method: internal reference pricing against comparable registered alternatives, external reference pricing against a list of reference countries, and review of clinical and economic studies. It also lists triggers for repricing (such as a therapeutic class review, renewal, GCC price unification or a change of marketing authorisation holder), a cap on price reductions per five-year product cycle, and published pricing decisions.
Margins. The same summary sets wholesale and pharmacy margins by price band:
| Ex-factory or CIF price (SAR) | Wholesale margin | Pharmacy margin |
|---|---|---|
| 50 or below | 15% | 20% |
| Above 50 to 200 | 10% | 15% |
| Above 200 | 10% | 10% |
Source: SFDA, pharmaceutical pricing summary for the PPRI network, 2024. Fixed margins matter for trade strategy: because the pharmacy margin is set by rule, competition for pharmacy support moves to service, availability, training and trade terms. The guide to pharmacy channel management in Saudi Arabia covers that side.
Public purchasing. The summary states that group purchasing at national level is processed through the National Unified Procurement Company for Medical Supplies (NUPCO), and that the CIF price set by SFDA is the ceiling for tendering and the starting point for negotiation. A product therefore needs its SFDA price before it can compete in a tender.
Government hospitals. Medicines are used in each hospital through mostly positive, open formularies, with a pharmacy and therapeutics (P&T) committee setting inclusion criteria each financial year within a set budget. For a specialist product, the hospital committee is often where access is won or lost.
Private sector. Medicines approved by SFDA can be covered depending on the co-payment, the insurer’s policy and prescriber behaviour, under the oversight of the Council of Health Insurance (formerly the Council of Cooperative Health Insurance).
| Access step in Saudi Arabia | Main counterpart | What the company prepares |
|---|---|---|
| Registration | SFDA | Registration dossier, product information, labelling |
| Pricing | SFDA pricing directorate and committee | Reference country prices, comparator analysis, economic studies |
| Public purchasing | NUPCO | Tender submissions, supply plans, price offers within the SFDA ceiling |
| Hospital formulary | Hospital P&T committees | Formulary submission, place in therapy, budget impact for the hospital, specialist support |
| Private coverage | Insurers, under the Council of Health Insurance | Value evidence, coverage requests, pharmacy and prescriber education |
The register also shows how crowded a therapy area is before you enter it. The Saudi drug registration statistics count registered products by category, which is useful context for the comparator and pricing analysis.
How Is a Market Access Team Organised?
Access is a team sport: strategy, health economics, pricing, account work and policy, connected to medical, marketing and finance.
| Role | Main responsibility |
|---|---|
| Market access head or manager | Access strategy across products; owner of the access plan |
| Health economics and outcomes research (HEOR) | Economic models, evidence generation, real-world data |
| Pricing | Price strategy, reference price monitoring, submissions |
| Key account or regional access managers | Formulary and tender work with hospitals, clusters and procurement bodies |
| Policy and government affairs | Health policy monitoring and engagement within the rules |
In smaller affiliates one or two people cover all of this, drawing on regional or global HEOR support. Whatever the size, access only works when it is planned with medical affairs (evidence and scientific exchange), marketing (positioning and brand plan), regulatory affairs (registration timing and labelling), finance (price and forecast) and the key account teams who manage the hospitals. The guide to the pharma marketing career shows where access roles sit on the wider commercial ladder.
Which KPIs Measure Market Access?
Measure the share of patients and accounts where the product can actually be used, the time it took, and the price achieved.
| KPI | Definition | Why it matters |
|---|---|---|
| Formulary coverage | Target hospitals that list the product, as a share of all target hospitals (or weighted by patients) | Shows where physicians can prescribe it |
| Covered lives or patients | Share of the target population whose payer or insurer covers the product | Shows how many patients can get it without paying in full |
| Time to access | Months from approval to price, and from price to first formulary or tender award | Every month of delay is lost patients and lost revenue |
| Tender win rate | Tenders won as a share of tenders entered, by volume or value | Tracks public sector competitiveness |
| Net price achieved | Average realised price after discounts and agreements, against plan | Shows whether access was bought at too high a cost |
| Restriction level | Share of listings with conditions such as specialist-only or second-line use | Restrictions shape the real patient pool |
These sit next to the brand’s commercial measures. The pharma marketing KPI library covers the rest of the dashboard.
How Do You Build a Market Access Plan? Seven Steps
Start early, map the decision makers, build the evidence they need, set the price strategy, then work account by account.
- Map the access landscape. For your product and country, list every decision: price, coverage, national and hospital formularies, tenders. Note who decides, on what evidence, on what timeline.
- Define the target population and place in therapy. Which patients, at which line of treatment, instead of what? A narrow, well-defined group is often easier to fund than a broad one. The patient journey map helps here.
- Build the value story and dossier. Unmet need, comparative evidence, economic value and budget impact, adapted to local data.
- Set the price strategy. Reference prices, local comparators, the price the payer can accept, the margin structure, and how the local price affects prices in other countries.
- Plan the submissions and timeline. Pricing, tenders and formularies each have their own calendars. Work backwards from tender and committee dates.
- Prioritise accounts. Rank hospitals and payers by patient volume and likelihood of listing; plan each one with the key account and medical teams. The field force needs to know where the product is listed before it promotes.
- Track and adjust. Review the access KPIs every month in the first year; feed what committees and payers say back into evidence generation.
What Are Common Market Access Mistakes?
Starting too late and treating access as paperwork are the two that cost the most.
| Mistake | Consequence | Fix |
|---|---|---|
| Starting after approval | Months lost waiting for price, tenders and committees | Start the access plan at least alongside the registration submission |
| Using global evidence only | Payers question relevance to their population and budget | Adapt the dossier and budget impact to local data |
| Promoting before listing | Physicians want to prescribe but cannot; trust drops | Sequence promotion account by account, after listing |
| Ignoring the hospital budget holder | Strong clinical support, but no listing | Include pharmacy and finance needs in the formulary submission |
| Working in silos | Medical, marketing and access tell different stories | One value story and one access plan owned jointly |
Key Takeaways
- Market access makes a medicine available and funded for the patients who need it; approval alone is not enough
- Decision makers include pricing authorities, payers, insurers, HTA bodies, procurement bodies and hospital committees
- Payers ask about unmet need, comparative benefit, value for money and budget impact; the value dossier answers them
- The main routes are pricing, reimbursement or coverage, formulary listing, tenders and HTA
- In Saudi Arabia, SFDA prices with reference pricing and set margins, NUPCO handles consolidated public purchasing, hospital P&T committees decide formulary use, and private coverage sits under the Council of Health Insurance
- Measure formulary coverage, covered patients, time to access, tender win rate and net price
- Start access planning early and work account by account with medical and key account teams
Frequently Asked Questions
What is market access in the pharmaceutical industry?
Market access is the work of making sure patients who need a medicine can actually get it, at a price the health system accepts and the company can sustain. It covers pricing, reimbursement and insurance coverage, inclusion on national and hospital formularies, public tenders, and health technology assessment. A product can be approved by the regulator and still fail commercially if it lacks access.
What is the difference between regulatory approval and market access?
Regulatory approval answers whether a medicine is safe, effective and of good quality enough to be sold. Market access answers whether the health system will pay for it and make it available to patients, and under which conditions. Approval comes from the medicines regulator; access decisions come from pricing authorities, payers, insurers, procurement bodies and hospital committees, which look at value, budget and alternatives as well as clinical evidence.
What does a market access manager do?
A market access manager plans and delivers the access of a company's products: maps the payers and decision makers, builds the value story and dossiers, prepares pricing and reimbursement submissions, supports formulary and tender work with hospital and procurement teams, works with health economists on models, and tracks access across accounts and regions. The role sits between medical, marketing, finance, regulatory and key account teams.
What is a value dossier?
A value dossier is a structured document that sets out the evidence for a medicine's value to payers: the disease burden and unmet need, the clinical evidence, comparisons with alternatives, health economic analyses such as cost-effectiveness and budget impact, and the proposed place in therapy. Companies often build a global dossier and adapt it for each country's requirements.
What is health technology assessment (HTA)?
Health technology assessment is a structured evaluation of a medicine or other health technology's clinical and economic value, used by health systems to decide what to pay for. It usually compares the new product with current practice, looks at clinical benefit, cost-effectiveness, budget impact and sometimes wider social and ethical factors. Many countries have dedicated HTA bodies; others build HTA into pricing and formulary decisions.
How does market access work in Saudi Arabia?
In Saudi Arabia a medicine is registered and priced by the Saudi Food and Drug Authority (SFDA). SFDA's 2024 summary of its pricing process describes internal and external reference pricing and economic review, set wholesale and pharmacy margins, and the SFDA price as the ceiling for public tenders. Public purchasing is consolidated through the National Unified Procurement Company (NUPCO). Government hospitals decide inclusion through pharmacy and therapeutics committees within their budgets, and private insurance coverage sits under the Council of Health Insurance and insurers' policies. Check current rules before you plan.
Is market access only for prescription medicines?
It matters most for prescription medicines, which are paid for largely by governments and insurers. OTC and consumer health products face access questions too, but of a different kind: pricing rules where they apply, distributor and pharmacy chain listings, and shelf space. Those are usually handled by sales, key account and trade marketing teams rather than a market access team.
What to Do Next
Take one product, launched or coming, and write its access map on a single page: every decision, the decision maker, the evidence they need, and the date of their next meeting or tender. The gaps on that page are your access plan for the next quarter.
To connect access with the rest of the launch, read the go-to-market strategy guide. For the scientific side of working with specialists and committees, read the guide to the medical science liaison role. For the rules on what may be said to healthcare professionals, see SFDA marketing compliance.
